
Last updated: 2026-09-16 09:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
GH Research PLC (GHRS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $27.75, with a market capitalisation of $1.91B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.04 to $31.44. This page covers its latest market performance, valuation, price trends and company information.
$1.91B | |
$27.66 | |
$31.44 | |
$5.05 | |
$27.55 | |
-- | |
276.02K | |
-- | |
$31.44 | |
$12.04 | |
-- | |
-- |
GH Research PLC (GHRS) is trading at $27.75 in pre-market trading as of 2026-09-16 08:04:00, up 0.72% ($0.20) from the previous close of $27.55
Pre-market trading shows how investors are pricing GHRS before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, GH Research PLC (GHRS) moved from $28.23 to $27.75, representing a decline of 1.70% ($0.48).
The stock traded between $26.46 and $28.62 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 174.56 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 81.0%
GHRS is currently trading at $27.75, placing it 81.0% of the way from its 52-week low of $12.04 to its 52-week high of $31.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
| Employees | 73 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of GH Research PLC (GHRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.